Literature DB >> 4358055

Zoster immune globulin. A further assessment.

A A Gershon, S Steinberg, P A Brunell.   

Abstract

Mesh：

Substances：

Year:  1974        PMID： 4358055     DOI： 10.1056/NEJM197401312900503

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  38 in total

1.  Antibody to varicella-zoster virus after passive immunization against chickenpox.

Authors:  A A Gershon; S Piomelli; M Karpatkin; E Smithwick; S Steinberg
Journal:  J Clin Microbiol       Date:  1978-12       Impact factor: 5.948

Review 2.  Antiviral therapy: current concepts and practices.

Authors:  B Bean
Journal:  Clin Microbiol Rev       Date:  1992-04       Impact factor: 26.132

Review 3.  Congenital varicella syndrome: the evidence for secondary prevention with varicella-zoster immune globulin.

Authors:  Arlan Cohen; Panagis Moschopoulos; Panagis Maschopoulos; Richard E Stiehm; Gideon Koren
Journal:  CMAJ       Date:  2011-01-24       Impact factor: 8.262

4.  Quantitation of antibodies to varicella-zoster virus by immune adherence hemagglutination.

Authors:  C L Wong; S Castriciano; M A Chernesky; W E Rawls
Journal:  J Clin Microbiol       Date:  1978-01       Impact factor: 5.948

5.  Specific immunoglobulin responses after varicella and herpes zoster.

Authors:  J E Cradock-Watson; M K Ridehalgh; M S Bourne
Journal:  J Hyg (Lond)       Date:  1979-04

Review 6.  Pathogenesis and current approaches to control of varicella-zoster virus infections.

Authors:  Anne A Gershon; Michael D Gershon
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

7.  COMMENTARY: Significantly less anti-gC antibody detectable in sera collected after varicella vaccination than after the disease varicella.

Authors:  Charles Grose; Young Juhn
Journal:  Pediatr Infect Dis J       Date:  2012-11       Impact factor: 2.129

8.  Human leukocyte interferon in the treatment of varicella in children with cancer: a preliminary controlled trial.

Authors:  A M Arvin; S Feldman; T C Merigan
Journal:  Antimicrob Agents Chemother       Date:  1978-04       Impact factor: 5.191

9.  Monoclonal antibodies against three major glycoproteins of varicella-zoster virus.

Authors:  C Grose; D P Edwards; W E Friedrichs; K A Weigle; W L McGuire
Journal:  Infect Immun       Date:  1983-04       Impact factor: 3.441

10.  Nosocomial varicella. Part II: suggested guidelines for management.

Authors:  G F Hayden; J D Meyers; R E Dixon
Journal:  West J Med       Date:  1979-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.